Amylyx Pharmaceuticals Inc (AMLX) returns
Amylyx Pharmaceuticals returns over 3 years
$1,000 invested in Amylyx Pharmaceuticals three years ago was worth $1,832 at the close on October 30, 2026, with dividends reinvested: an average return of 22.4% a year. The same $1,000 in the S&P 500 (SPY) became $1,885.
Total return by period
| Period | Total return | A year, on average | $1,000 became | S&P 500 (SPY) |
|---|---|---|---|---|
| 1 month | -0.8% | — | $991.75 | -0.9% |
| 3 months | +39.1% | — | $1,391 | +2.1% |
| Year to date | +138.9% | — | $2,389 | +11.7% |
| 1 year | +105.4% | — | $2,054 | +12.4% |
| 3 years | +83.2% | +22.4% | $1,832 | +88.5% |
Amylyx Pharmaceuticals return by calendar year
| Year | AMLX | S&P 500 (SPY) | Difference |
|---|---|---|---|
| 2026 to date | +138.9% | +11.7% | +127.2% |
| 2025 | +219.6% | +17.7% | +201.9% |
| 2024 | -74.3% | +24.9% | -99.2% |
| 2023 | -60.2% | +26.2% | -86.4% |
Past returns do not predict future returns. Returns are computed from our daily closes, adjusted for splits and with dividends reinvested on their ex-dates; taxes and trading costs are left out.
See also: AMLX financials
No forecast, no recommendation. This page describes Amylyx Pharmaceuticals Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.